An observational study in Chronic Kidney Disease, sponsored by Instituto de Investigación Biomédica de Salamanca. Recruiting at 1 site in Spain. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Instituto de Investigación Biomédica de Salamanca · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 188 studies in Renal Insufficiency, Chronic with a site in Spain — 38 open to participants now, 55 under way, 23 of them phase 3. Renal Insufficiency, Chronic · Spain.
Among the 188 studies in Renal Insufficiency, Chronic with a site in Spain, this one is the 20th largest by planned enrollment of the 34 observational ones that give a count, is one of 15 that started in 2026, is one of 34 observational ones, reaches primary completion later than 35 of the 54 other live ones, and was the 169th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →38 of the 188 studies in Renal Insufficiency, Chronic with a site in Spain are open now. Recruiting first, the newest first:
Cardenal Herrera University · Sites in Spain
Ages 18–85
AstraZeneca · Sites in Spain, United States, Argentina and 24 more countries
Ages 18–99
AstraZeneca · Sites in Spain, United States, Argentina and 34 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Spain, United States, China and 5 more countries
Ages 2–18
Vifor Fresenius Medical Care Renal Pharma · Sites in Spain, China, Greece and 4 more countries
Ages 12–18
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
188 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 34 · Phase 3 80 · Phase 4 14
First in 1998; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 213 across 835 observational studies indexed under Renal Insufficiency, Chronic.
Median enrollment 252 across the 154 interventional studies, 397 across the 34 observational. Of the 122 that completed or were terminated, 68 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
124 of 188 have an industry lead sponsor. The 10 most frequent:
Instituto de Investigación Biomédica de Salamanca is the lead sponsor of 20 studies on the registry; 15 are open to participants now.
Instituto de Investigación Biomédica de Salamanca has 1 study filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
13 of the studies in Renal Insufficiency, Chronic with a site in Spain that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06578078Phase 3Fundación para la Investigación del Hospital Clínico de ValenciaA Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients | 2026-12-30 |
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT07107945Phase 3Boehringer IngelheimA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | 2027-04-16 |
| NCT03969329Phase 3AmgenA Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis | 2027-06-30 |
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
Add all 13 to your calendar (.ics) → With an account.
Among the 188 studies in Renal Insufficiency, Chronic with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective observational study aims to assess the association between real-world use of sodium-glucose co-transporter 2 inhibitors (SGLT2i; e.g., empagliflozin, dapagliflozin) and renal function decline in adults with chronic kidney disease (CKD) stages 2-4 (KDIGO classification). The study will also validate a urinary biomarker panel for early diagnosis and monitoring of CKD progression.
No investigational product is assigned, and medical practice or prescription patterns are not altered.
This is a real-world, observational study with prospective follow-up and retrospective baseline data when available, conducted at the Nephrology Department of the University Hospital of Salamanca, Spain.
The project integrates translational and clinical components:
A total of 300 adults with CKD stages 2-4 will be included (150 initiating SGLT2i and 150 matched controls). Participants will be followed for 12 months (baseline, 6, and 12 months). Data will be extracted exclusively from electronic health records and laboratory systems.
The primary outcome is the annual decline rate of estimated glomerular filtration rate (eGFR, CKD-EPI 2021). Secondary outcomes include a composite renal endpoint (≥40% sustained eGFR decline, renal replacement therapy, transplantation, or renal death), cardiovascular hospitalization, all-cause mortality, adverse drug reactions (ADRs), and real-world patterns of SGLT2i use.
Exploratory analyses will assess associations between urinary biomarkers and clinical outcomes.
The study follows Spanish regulations for observational studies with medicinal products (Real Decreto 957/2020), with ethics approval and informed consent for biological samples.
Participants with chronic kidney disease (CKD) stages 2-4.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with chronic kidney disease (CKD) stages 2-4 will receive oral empagliflozin (10-25 mg daily) for 12 months. Urinary and plasma samples will be collected at baseline, 6 months, and 12 months to evaluate the urinary biomarker panel, renal function (eGFR), and treatment safety.
Drug: Empagliflozin
Adults with chronic kidney disease (CKD) stages 2-4 (KDIGO classification) managed in nephrology outpatient clinics without initiation of SGLT2 inhibitors at baseline or during follow-up. These patients receive standard clinical care according to local and national guidelines. They are followed on the same schedule (baseline, 6, and 12 months) and have identical variables collected from electronic health records and laboratory systems. Reasons for non-initiation of SGLT2i are documented systematically and may include: Not meeting indication criteria established by the Spanish National Health System (e.g., albumin-to-creatinine ratio \<200 mg/g, eGFR \<20 mL/min/1.73 m² for empagliflozin or \<25 for dapagliflozin), or Clinical contraindications or conditions such as significant hypovolemia or hypotension, recurrent urinary or genital infections, or hypersensitivity. Control patients will be censored in the primary analysis if they later start SGLT2i therapy (cross-over).
Oral empagliflozin (10-25 mg daily) for 12 months
Change in urinary biomarker panel expression (proteomic fingerprint)
Quantitative assessment of urinary biomarkers (including KIM-1, transferrin, IGFBP7, TIMP-2, among others) to evaluate disease progression and treatment response. Urinary biomarkers will be assessed using liquid chromatography-mass spectrometry (LC-MS/MS)-based differential proteomic analysis. Biomarker expression will be quantified as log2 fold change with false discovery rate (FDR) correction. Selected biomarkers will be validated using enzyme-linked immunosorbent assay (ELISA) or equivalent immunoassays. Biomarker concentrations will be normalized to urinary creatinine levels.
Time frame: Baseline, 6 months, 12 months
Change in estimated glomerular filtration rate (eGFR)
Evaluation of renal function improvement or stabilization during SGLT2 inhibitor treatment.
Time frame: Baseline, 6 months, 12 months
Histopathological improvement of renal tissue (animal study)
Monthly analysis of renal fibrosis, inflammation, and extracellular matrix accumulation in preclinical models treated with empagliflozin.
Time frame: Monthly up to 9 months
Monitoring of adverse events of empagliflozin in CKD patients without diabetes
Adverse events (AEs) will be recorded and classified according to Common Terminology Criteria for Adverse Events (CTCAE, latest version), including severity grading and assessment of causality related to treatment. Serious adverse events (SAEs) and discontinuations due to AEs will be specifically tracked by the investigator.
Time frame: From baseline to 12 months
Change in estimated glomerular filtration rate (eGFR)
Change in renal function assessed by estimated glomerular filtration rate (eGFR) calculated using the CKD-EPI equation during empagliflozin treatment using the Serum creatinine-based CKD-EPI equation.
Time frame: From baseline to 12 months
Change in serum creatinine
hange in serum creatinine levels to assess renal safety during treatment with empagliflozin by standard clinical laboratory assay (mg/dL).
Time frame: From baselinte to 12 months
Change in urinary albumin-to-creatinine ratio
Change in urinary albumin-to-creatinine ratio as a marker of renal damage and safety during empagliflozin treatment by standard urine laboratory testing (mg/g creatinine).
Time frame: From baseline to 12 months
Change in serum electrolyte levels
Change in serum sodium and potassium levels to evaluate electrolyte safety during empagliflozin treatment by standard clinical laboratory testing (mmol/L).
Time frame: From baseline to 12 months
Change in liver function tests
Change in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels to assess hepatic safety by standard clinical laboratory assays (U/L).
Time frame: From baseline to 12 months
Change in glycated hemoglobin (HbA1c)
Change in HbA1c levels to monitor metabolic safety in non-diabetic CKD patients treated with empagliflozin by standard laboratory assay (%).
Time frame: From baseline to 12 months.
Change in hematological parameters
Change in complete blood count parameters to evaluate hematological safety during treatment by standard clinical laboratory testing.
Time frame: From baseline to 12 months
Change in blood pressure
Assessment of changes in both blood pressures (systolic and diastolic), by Standard sphygmomanometer measurement (mmHg).
Time frame: From baseline to 12 months
Change in body weight
Change in body weight to assess tolerability and volume status during empagliflozin treatment by calibrated clinical scale (kg).
Time frame: From baseline to 12 months
Discontinuation due to treatment intolerance
Number and proportion of participants who permanently discontinue empagliflozin due to treatment-related intolerance or adverse events. It will be achieved trough clinical visit records and adverse event reporting.
Time frame: From baseline to 12 months
Plan to share: Yes — Anonymized datasets and analytic code will be available upon reasonable request, following approval by the Ethics Committee and IBSAL data governance board.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: Data will be available starting 12 months after publication of primary results and for a minimum of 5 years thereafter.
Access criteria: Qualified researchers with a methodologically sound proposal, as determined by the study steering committee, will be able to access the data. Requests should be directed to the study PI. A data access agreement will be required.
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Apr 2028, 24 months after the start.
Of 276 non-industry observational studies under Renal Insufficiency, Chronic, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 192. This study's planned 24 months is below that.
Counting every sponsor, half of 327 studies reached it within 45 months; a quarter within 22 and three quarters within 191.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: start Jan 2026 → Apr 2026, primary completion Dec 2027 → Apr 2028 and completion Mar 2028 → Dec 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →
Instituto de Investigación Biomédica de Salamanca